ClinicalTrials.gg
RecruitingNCT06868732Updated Mar 30, 2026

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

A Phase 1 interventional study of JSKN016 and Carboplatin in Advanced Non-small Cell Lung Cancer, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
288
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
7th of 41
288 · median 60
Started
2025
with 6 others
Phase 1
4 of 41
1 open now
Primary completion
2028-06
later than 25 of 33 live
Registered
26th of 41
by date

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by planned enrollment, is one of 7 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 25 of the 33 other live ones, and was the 26th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.

Read the detailed description

This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer. The primary objective of the study is to assess the efficacy and safety of JSKN016 in combination therapy in selected subjects with advanced non-small cell lung cancer.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form.
  2. Age ≥ 18 years old, ≤ 75 years old, male or female.
  3. performance status (ECOG PS) score of 0 or 1.
  4. Expected survival ≥ 3 months.
  5. or cytologically confirmed locally advanced or non-small cell lung cancer (NSCLC) that is not suitable for radical surgery and/or radical radiotherapy.
  6. At least one extracranial at baseline according to 1.1 criteria.
  7. Recently archived or fresh tumor tissue samples are available.
  8. Have good organ function.
  9. Have no current birth plans and agree to during the trial.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any small cell carcinoma component in histopathology.
  2. Subjects with other malignant tumors within 5 years prior to enrollment, and other tumors have been cured through local therapy, such as cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-primary invasive bladder cancer, and prostate/cervical/breast cancer in situ.
  3. Presence of brainstem, meningeal , spinal cord metastases or compression, , or history of carcinomatous meningitis; Presence of active .
  4. During the screening period, imaging shows that the tumor invades, compresses, or occurs in the surrounding important organs (such as the heart and pericardium, trachea, esophagus, superior vena cava, etc.) or there is a risk of esophageal tracheal fistula or esophageal pleural fistula.
  5. Adequate of previous therapy before the first dose.
  6. Gastrointestinal abnormalities with obvious clinical manifestations.
  7. Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
  8. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  9. Prior treatment with topoisomerase I inhibitors (e.g., irinotecan, topotecan), antibody-drug conjugates containing topoisomerase I inhibitors (e.g., DS-8201, HER3-DXd, DS-1062), or targeting TROP2 or HER3.
  10. Previous treatment with docetaxel.
  11. Have an uncontrolled infection, a history of immunodeficiency, a positive (HIV) test, or a history of AIDS.
  12. Previous history of allogeneic bone marrow or organ transplantation.
  13. Known allergy to any component of the study drug, and previous history of severe allergic reaction to other antibody drugs.
  14. Pregnant and/or lactating females.
  15. Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which can lead to higher medical risk and/or uncertainty in survival evaluation, such as tumor leukemia response , cachexia manifestations, etc.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    Cohort -1A-a

    Receive JSKN016 in combination with carboplatin, administered intravenously at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Carboplatin

  • Experimental
    Cohort -1A-b

    Receive JSKN016 in combination with furmonertinib mesilate tablets, administered at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Furmonertinib Mesylate

  • Experimental
    Cohort -1B

    Receive JSKN016 in combination with ivonescimab, administered intravenously at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Ivonescimab

  • Experimental
    Cohort -2

    Receive JSKN016 in combination with docetaxel, administered intravenously at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Docetaxel

  • Experimental
    Cohort -3A

    Receive JSKN016 in combination with tislelizumab,with or without carboplatin, administered intravenously at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Carboplatin · Drug: Tislelizumab

  • Experimental
    Cohort -3B

    Receive JSKN016 in combination with ivonescimab,with or without carboplatin, administered intravenously at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Carboplatin · Drug: Ivonescimab

  • Experimental
    Cohort -4

    Receive JSKN016 in combination with pembrolizumab, administered intravenously at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Pembrolizumab

  • Experimental
    Cohort -5

    Receive JSKN016 in combination with furmonertinib mesilate tablets, administered at the dosage specified in the protocol.

    Drug: JSKN016 · Drug: Furmonertinib Mesylate

Interventions

  • Administered intravenously according to protocol.

  • AUC 5, Q3W, administered intravenously according to protocol.

    Also known as: Carboplatin Injection

  • 160mg(cohort1A-b)or 80mg(cohort 5), qd, administered according to protocol.

    Also known as: Furmonertinib Mesylate Tablets

  • 20mg/kg, Q3W, administered intravenously according to protocol.

    Also known as: Ivonescimab Injection

  • 60mg/m\^2, Q3W, administered intravenously according to protocol.

    Also known as: Docetaxel injection

  • 200mg, Q3W, administered intravenously according to protocol.

    Also known as: Tislelizumab Injection

  • 200mg, Q3W, administered intravenously according to protocol.

    Also known as: Pembrolizumab Injection

06

What researchers measure

Primary outcomes

  1. ORR assessed by the investigator per RECIST v1.1

    Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: Up to 24months

  2. Safety reflected by AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to 24months

Secondary outcomes

  1. DOR assessed by the investigator per RECIST v1.1

    Duration of response (DoR) assessed according to RECIST v1.1.

    Time frame: Up to 24months

  2. DCR assessed by the investigator per RECIST v1.1

    Disease control rate (DCR) assessed according to RECIST v1.1.

    Time frame: Up to 24months

  3. TTR assessed by the investigator per RECIST v1.1

    Time to response (TTR) is defined as the time to response base on RECIST v1.1.

    Time frame: Up to 24months

  4. PFS assessed by investigator per RECIST v1.1

    Progression-free survival (PFS) is defined as the time from the date of initial administration till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first).

    Time frame: Up to 24months

  5. OS

    Overall Survival (OS) is defined as the time from the date of initial administration till death due to any cause.

    Time frame: Up to 24months

  6. Peak Plasma Concentration (Cmax)

    The Peak Plasma Concentration (Cmax) of the antibody-drug conjugate (ADC), total antibody and free payload.

    Time frame: Up to 24months

  7. Trough Plasma Concentration (Cmin)

    The Trough Plasma Concentration (Cmin) of the antibody-drug conjugate (ADC), total antibody and free payload.

    Time frame: Up to 24 months

  8. ADA

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: Up to 24months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2028, 38 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 38 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 11, 2025
StartActual
Apr 2, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06868732
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Apr 2, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Li Zhang
Contact
zhangli@sysucc.org.cn
13902282893
Li Zhang
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: JSKN016 · Aflutinib

Start the discussion